Across TCGA pan-cancer cohorts, BTBD9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTBD9 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BTBD9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BTBD9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and OV are the cancer types where BTBD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.973	0.847	.012	6	view →
LUAD	OS	Tertile	II,III,IV	0.819	0.498	.025	6	view →
OV	DFS	Median	All	1.000	0.716	.046	4	view →
CCRCC	DFS	Tertile	All	1.000	0.434	.020	3	view →
HNSC	OS	Median	II,III,IV	0.612	0.799	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BTBD9 tumor-vs-normal RNA expression · all BTBD9 data types